54.16
-0.05 (-0.09%)
| Penutupan Terdahulu | 54.21 |
| Buka | 54.07 |
| Jumlah Dagangan | 43,798 |
| Purata Dagangan (3B) | 255,664 |
| Modal Pasaran | 1,138,324,096 |
| Harga / Pendapatan (P/E Ke hadapan) | 8.95 |
| Harga / Jualan (P/S) | 1.92 |
| Harga / Buku (P/B) | 2.88 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| Margin Keuntungan | -1.28% |
| Margin Operasi (TTM) | -7.34% |
| EPS Cair (TTM) | -0.470 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 12.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 146.78% |
| Nisbah Semasa (MRQ) | 2.74 |
| Aliran Tunai Operasi (OCF TTM) | 92.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 50.11 M |
| Pulangan Atas Aset (ROA TTM) | 1.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -1.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | ANI Pharmaceuticals, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -4.0 |
| Purata | 0.63 |
|
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 10.54% |
| % Dimiliki oleh Institusi | 100.57% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 94.00 (HC Wainwright & Co., 73.56%) | Beli |
| Median | 74.00 (36.63%) | |
| Rendah | 62.00 (Truist Securities, 14.48%) | Pegang |
| Purata | 76.00 (40.33%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 59.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Leerink Partners | 11 Dec 2024 | 80.00 (47.71%) | Beli | 59.17 |
| HC Wainwright & Co. | 11 Nov 2024 | 94.00 (73.56%) | Beli | 61.74 |
| Truist Securities | 22 Oct 2024 | 62.00 (14.48%) | Pegang | 60.08 |
| Piper Sandler | 11 Oct 2024 | 68.00 (25.55%) | Beli | 57.14 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |